Xeris Biopharma Holdings, Inc. (XERS) Q2 FY26 Earnings Call

Record Recorlev growth, a raised revenue floor, and XP8121 Phase 3 timing define the strongest signals [14][19][37].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-06
Length38 minutes
EPS$0.00
EPS consensus$0.02
Revenue$83.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY25

All XERS earnings ยท Back to XERS overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.